Your browser doesn't support javascript.
loading
STIMULUS-MDS2 design and rationale: a phase III trial with the anti-TIM-3 sabatolimab (MBG453) + azacitidine in higher risk MDS and CMML-2.
Zeidan, Amer M; Giagounidis, Aristoteles; Sekeres, Mikkael A; Xiao, Zhijian; Sanz, Guillermo F; Hoef, Marlies Van; Ma, Fei; Hertle, Sabine; Santini, Valeria.
Affiliation
  • Zeidan AM; Yale University & Yale Cancer Center, New Haven, CT 06510, USA.
  • Giagounidis A; Marien Hospital Düsseldorf, Düsseldorf, 40479, Germany.
  • Sekeres MA; Division of Hematology, Sylvester Cancer Center, University of Miami, Miami, FL 33065, USA.
  • Xiao Z; Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, 300020, China.
  • Sanz GF; Hospital Universitario y Politécnico La Fe, Valencia, 46026, Spain.
  • Hoef MV; Health Research Institute La Fe (IIS La Fe), Valencia, 46026, Spain.
  • Ma F; CIBERONC, Instituto de Salud Carlos III, Madrid, 28029, Spain.
  • Hertle S; Novartis Pharma AG, Basel, 4056, Switzerland.
  • Santini V; Novartis Pharmaceuticals Corporation, East Hanover, NJ 07936, USA.
Future Oncol ; 19(9): 631-642, 2023 Mar.
Article in En | MEDLINE | ID: mdl-37083373

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Myelodysplastic Syndromes / Leukemia, Myelomonocytic, Chronic / Leukemia, Myeloid, Acute Type of study: Etiology_studies / Risk_factors_studies Limits: Humans Language: En Journal: Future Oncol Year: 2023 Document type: Article Affiliation country: United States Country of publication: United kingdom

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Myelodysplastic Syndromes / Leukemia, Myelomonocytic, Chronic / Leukemia, Myeloid, Acute Type of study: Etiology_studies / Risk_factors_studies Limits: Humans Language: En Journal: Future Oncol Year: 2023 Document type: Article Affiliation country: United States Country of publication: United kingdom